Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2016 1
2017 2
2018 2
2019 5
2020 3
2021 3
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy.
Borch A, Bjerregaard AM, Araujo Barbosa de Lima V, Østrup O, Yde CW, Eklund AC, Mau-Sørensen M, Barra C, Svane IM, Nielsen FC, Funt SA, Lassen U, Hadrup SR. Borch A, et al. Among authors: yde cw. Front Genet. 2023 Mar 23;14:1058605. doi: 10.3389/fgene.2023.1058605. eCollection 2023. Front Genet. 2023. PMID: 37035751 Free PMC article.
New pathogenic germline variants identified in mesothelioma.
Belcaid L, Bertelsen B, Wadt K, Tuxen I, Spanggaard I, Højgaard M, Benn Sørensen J, Ravn J, Lassen U, Cilius Nielsen F, Rohrberg K, Westmose Yde C. Belcaid L, et al. Among authors: westmose yde c. Lung Cancer. 2023 May;179:107172. doi: 10.1016/j.lungcan.2023.03.008. Epub 2023 Mar 15. Lung Cancer. 2023. PMID: 36944283 Free article. Review.
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T, Højgaard M, Rohrberg K, Spanggaard I, Laursen BE, Ladekarl M, Haslund CA, Harsløf L, Belcaid L, Gehl J, Søndergaard L, Eefsen RL, Hansen KH, Kodahl AR, Jensen LH, Holt MI, Oellegaard TH, Yde CW, Ahlborn LB, Lassen U. Kringelbach T, et al. Among authors: yde cw. BMC Cancer. 2023 Feb 22;23(1):182. doi: 10.1186/s12885-023-10632-9. BMC Cancer. 2023. PMID: 36814246 Free PMC article. Clinical Trial.
Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.
Jacobsen IC, Spanggaard I, Højgaard M, Belcaid L, Qvortrup C, Yde CW, Schmidt AY, Nielsen FC, Willemoe GL, Dam MS, Lassen U, Staal Rohrberg K. Jacobsen IC, et al. Among authors: yde cw. Acta Oncol. 2022 Dec;61(12):1499-1506. doi: 10.1080/0284186X.2022.2156809. Epub 2022 Dec 18. Acta Oncol. 2022. PMID: 36529989
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Nielsen M, et al. Among authors: yde cw. Cancer Immunol Res. 2022 Oct 4;10(10):1254-1262. doi: 10.1158/2326-6066.CIR-22-0326. Cancer Immunol Res. 2022. PMID: 35969233
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Mørk SK, Kadivar M, Bol KF, Draghi A, Westergaard MCW, Skadborg SK, Overgaard N, Sørensen AB, Rasmussen IS, Andreasen LV, Yde CW, Trolle T, Garde C, Friis-Nielsen J, Nørgaard N, Christensen D, Kringelum JV, Donia M, Hadrup SR, Svane IM. Mørk SK, et al. Among authors: yde cw. Oncoimmunology. 2022 Jan 10;11(1):2023255. doi: 10.1080/2162402X.2021.2023255. eCollection 2022. Oncoimmunology. 2022. PMID: 35036074 Free PMC article.
A Comparison of Tools for Copy-Number Variation Detection in Germline Whole Exome and Whole Genome Sequencing Data.
Gabrielaite M, Torp MH, Rasmussen MS, Andreu-Sánchez S, Vieira FG, Pedersen CB, Kinalis S, Madsen MB, Kodama M, Demircan GS, Simonyan A, Yde CW, Olsen LR, Marvig RL, Østrup O, Rossing M, Nielsen FC, Winther O, Bagger FO. Gabrielaite M, et al. Among authors: yde cw. Cancers (Basel). 2021 Dec 14;13(24):6283. doi: 10.3390/cancers13246283. Cancers (Basel). 2021. PMID: 34944901 Free PMC article.
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Kverneland AH, Chamberlain CA, Borch TH, Nielsen M, Mørk SK, Kjeldsen JW, Lorentzen CL, Jørgensen LP, Riis LB, Yde CW, Met Ö, Donia M, Svane IM. Kverneland AH, et al. Among authors: yde cw. J Immunother Cancer. 2021 Oct;9(10):e003499. doi: 10.1136/jitc-2021-003499. J Immunother Cancer. 2021. PMID: 34607899 Free PMC article.
26 results